TOKYO – Though Japan's drug sector will maintain a pro-innovation policy with the aim to maximize patient value, discussions between the country's Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceutical Research and Manufacturers of America (PHRMA) showed stark differences in opinions.